Liposome-Based Drug Delivery Systems for Targeted Treatment of Breast Cancer
DOI:
https://doi.org/10.15662/IJRAI.2026.0902003Keywords:
Liposomes, Breast cancer, Targeted drug delivery, Nanomedicine, Chemotherapy, Pharmacokinetics, Cancer therapyAbstract
Liposome-based drug delivery systems have emerged as an effective nanotechnological strategy to overcome these limitations by improving drug solubility, stability, pharmacokinetics, and tumor targeting. Liposomes are biocompatible phospholipid vesicles capable of encapsulating both hydrophilic and hydrophobic anticancer agents, enabling controlled drug release and reduced off-target effects. This review provides a comprehensive overview of liposome-based drug delivery systems for targeted treatment of breast cancer. It discusses breast cancer pathophysiology and molecular targets relevant to liposomal design, followed by an in-depth analysis of liposome structure, formulation strategies, and physicochemical properties influencing therapeutic performance. Passive targeting via the enhanced permeability and retention (EPR) effect, active ligand-mediated targeting, and stimuli-responsive liposomal systems are critically examined. The review further highlights therapeutic applications including liposomal chemotherapeutics, combination drug delivery, and gene/siRNA delivery approaches. In vivo pharmacokinetics, biodistribution, clinical progress of approved liposomal formulations, and ongoing clinical developments are also discussed. Additionally, safety, toxicity, and regulatory considerations are addressed, along with key challenges hindering clinical translation. Finally, emerging trends such as multifunctional liposomes, personalized nanomedicine, and scalable manufacturing strategies are explored. Overall, liposome-based drug delivery systems represent a promising and clinically relevant platform for improving the efficacy and safety of breast cancer therapy.
References
[1] L. Wilkinson and T. Gathani, "Understanding breast cancer as a global health concern," The British journal of radiology, vol. 95, no. 1130, p. 20211033, 2022.
[2] M. M. Islam and S. Raikwar, "Enhancement of oral bioavailability of protein and peptide by polysaccharide-based nanoparticles," Protein and Peptide Letters, vol. 31, no. 3, pp. 209-228, 2024.
[3] S. Al-Mahmood, J. Sapiezynski, O. B. Garbuzenko, and T. Minko, "Metastatic and triple-negative breast cancer: challenges and treatment options," Drug delivery and translational research, vol. 8, no. 5, pp. 1483-1507, 2018.
[4] I. Hamad, A. A. Harb, and Y. Bustanji, "Liposome-based drug delivery systems in cancer research: an analysis of global landscape efforts and achievements," Pharmaceutics, vol. 16, no. 3, p. 400, 2024.
[5] M. M. Islam, A. Kumar, A. Kumar, D. Mukherjee, and M. Kumar, "Emerging Trends in Novel Drug Delivery Systems for the Effective Treatment of Oral Cancer," Current Cancer Therapy Reviews, vol. 21, no. 5, pp. 679-694, 2025.
[6] M. K. Riaz et al., "Surface functionalization and targeting strategies of liposomes in solid tumor therapy: A review," International journal of molecular sciences, vol. 19, no. 1, p. 195, 2018.
[7] U. Testa, G. Castelli, and E. Pelosi, "Breast cancer: a molecularly heterogenous disease needing subtype-specific treatments," Medical Sciences, vol. 8, no. 1, p. 18, 2020.
[8] A. Mazumder, S. Shiao, and S. Haricharan, "HER2 activation and endocrine treatment resistance in HER2-negative breast cancer," Endocrinology, vol. 162, no. 10, p. bqab153, 2021.
[9] M. Hajimolaali, F. A. Dorkoosh, and S. G. Antimisiaris, "Review of recent preclinical and clinical research on ligand-targeted liposomes as delivery systems in triple negative breast cancer therapy," Journal of Liposome Research, vol. 34, no. 4, pp. 671-696, 2024.
[10] H. Nsairat et al., "Liposome bilayer stability: emphasis on cholesterol and its alternatives," Journal of liposome research, vol. 34, no. 1, pp. 178-202, 2024.
[11] Y. Xia, J. Tian, and X. Chen, "Effect of surface properties on liposomal siRNA delivery," Biomaterials, vol. 79, pp. 56-68, 2016.
[12] M. M. Islam et al., "Formulation Development, Box-Behnken Design-Based Optimization and Evaluation of Cisplatin-Loaded Chitosan Nanoparticles Embedded in Mucoadhesive Buccal Film for Targeted Oral Cancer Therapy," Journal of Pharmaceutical Innovation, vol. 20, no. 6, p. 276, 2025.
[13] I.-A. Vagena, C. Malapani, M.-A. Gatou, N. Lagopati, and E. A. Pavlatou, "Enhancement of EPR effect for passive tumor targeting: current status and future perspectives," Applied Sciences, vol. 15, no. 6, p. 3189, 2025.
[14] F. S. Anarjan, "Active targeting drug delivery nanocarriers: Ligands," Nano-Structures & Nano-Objects, vol. 19, p. 100370, 2019.
[15] Y. Lee and D. Thompson, "Stimuli‐responsive liposomes for drug delivery," Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, vol. 9, no. 5, p. e1450, 2017.
[16] P. S. Zangabad et al., "Stimulus-responsive liposomes as smart nanoplatforms for drug delivery applications," Nanotechnology reviews, vol. 7, no. 1, pp. 95-122, 2018.
[17] M. El-Tanani, H. Nsairat, A. A. Aljabali, I. I. Matalka, A. M. Alkilany, and M. M. Tambuwala, "Dual-loaded liposomal carriers to combat chemotherapeutic resistance in breast cancer," Expert Opinion on Drug Delivery, vol. 21, no. 2, pp. 309-324, 2024.
[18] E. Zhang, R. Xing, S. Liu, and P. Li, "Current advances in development of new docetaxel formulations," Expert Opinion on Drug Delivery, vol. 16, no. 3, pp. 301-312, 2019.
[19] A. S. Correia, F. Gärtner, and N. Vale, "Drug combination and repurposing for cancer therapy: the example of breast cancer," Heliyon, vol. 7, no. 1, 2021.
[20] P. V. Teixeira, E. Fernandes, T. B. Soares, F. Adega, C. M. Lopes, and M. Lúcio, "Natural compounds: co-delivery strategies with chemotherapeutic agents or nucleic acids using lipid-based nanocarriers," Pharmaceutics, vol. 15, no. 4, p. 1317, 2023.
[21] H. Kaur, M. M. Islam, J. Kalita, A. Chauhan, H. K. Das, and A. Singh, "Exosomes in Oncology: Advancing Gene Therapy and Targeted Drug Delivery Systems," Clinical Cancer Drugs, vol. 11, no. 1, p. E2212697X314534, 2025.
[22] R. Borgohain, M. M. Islam, H. Kaur, H. Kaur, A. Kumar, and S. Raikwar, "Tiny Dots, Big Impact: The Antimicrobial Power of Carbon Dots," Anti-Infective Agents, vol. 23, no. 5, p. E22113525366977, 2025.
[23] T. Sharma, M. M. Islam, A. K. Lunawat, and S. Raikwar, "Targeting to Overexpressed Receptor in Colon Cancer: A Review," The International Journal of Gastroenterology and Hepatology Diseases, vol. 3, no. 1, p. E080724231732, 2024.
[24] M. M. Islam, A. Verma, and S. Raikwar, "PAMAM Dendrimers: Revolutionizing the Targeted Cancer Therapy," vol. 10, ed: Bentham Science Publishers, 2024, p. E110724231858.
[25] M. M. Islam, J. Kalita, S. Kaur, and A. Singh, "Targeting Cancer with Graphene Quantum Dots (GQDs): A Novel Approach," Clinical Cancer Drugs, vol. 11, no. 1, p. E2212697X350689, 2025.
[26] M. M. Islam and S. Raikwar, "Revolutionizing Oral Cancer Treatment: Immunotherapeutic Approaches," Current Cancer Therapy Reviews, vol. 21, no. 3, pp. 278-286, 2025.
[27] M. M. Islam et al., "Nanotechnology in Anti-EGFR Treatments: Enhancing Delivery and Minimizing Toxicity in Cancer Therapy," Clinical Cancer Drugs, vol. 11, no. 1, p. E2212697X377694, 2025.
[28] M. M. Islam and S. Raikwar, "Artificial Intelligence in the Development and Optimization of Nanocarriers," vol. 21, ed: Bentham Science Publishers, 2025, pp. 355-357.
[29] A. Verma, A. Chauhan, M. M. Islam, M. S. Kahlon, and A. Singh, "Navigating the Opioid Crisis: Exploring Innovative Approaches to Pain Management," Current Pharmaceutical Biotechnology, vol. 25, no. 13, pp. 1629-1631, 2024.
[30] A. Kumar, A. Kumar, M. M. Islam, R. Borgohain, and S. Raikwar, "Modern Solutions to UTIs: The Role of Nanotechnology and Herbal Treatments," Current Drug Targets, 2025.
